All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional.
The PsOPsA Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your PsOPsA Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe PsOPsA Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the PsOPsA Hub cannot guarantee the accuracy of translated content. The PsOPsA Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Quality of life after tildrakizumab treatment for plaque psoriasis: Results from a phase IV study
By Ella Dixon
|
Tildrakizumab, an anti-IL-23 mAb, is approved for the treatment of moderate-to-severe plaque psoriasis in adult patients.1 A phase IV real-world, open-label, US-based study (NCT03718299) was initiated to evaluate the effect of tildrakizumab on HRQoL in patients with plaque psoriasis. A total of 55 patients were enrolled; 45 patients completed 64 weeks of treatment and were subsequently assessed. The primary endpoint was improvement in PGWBI from baseline. Changes to DLQI and safety outcomes were also assessed.1
|
| Key learnings |
|
Significant improvements were observed in PGWBI and DLQI. The mean PGWBI score improved over time, increasing from 78.1 at baseline to 85.2 at Week 52 (p < 0.001). Mean DLQI score improved from 9.4 to 2.0 by Week 64 (p < 0.001). |
|
Significant improvements were seen in the PGWBI subdomains of positive well-being and general health. Other domains, such as anxiety and depression, showed improvement trends. |
|
At Week 64, 62.2% of patients reported minimal or no impact of psoriasis on their QoL (DLQI 0/1). These improvements were evident from Week 4, indicating rapid and sustained benefits, with the proportion of patients achieving DLQI 0/1 increasing over time. |
|
Overall, tildrakizumab demonstrated long-term effectiveness in enhancing both psychological and skin-related QoL, with no adverse events reported relating to tildrakizumab treatment. This real-world evidence strengthens confidence in tildrakizumab as a treatment for improving patient-reported outcomes. |
Abbreviations: DLQI, Dermatology Life Quality Index; HRQoL, health-related quality of life; IL, interleukin; mAb, monoclonal antibody; PGWBI, Psychological General Well-Being Index; QoL, quality of life.
- Bhatia N, Heim J, Vasquez JG, et al. Long-term quality of life outcomes from a phase 4 study of tildrakizumab in patients with moderate- to-severe plaque psoriasis in a real-world setting. J Dermatolog Treat. 2024;35(1):2310631. DOI: 10.1080/09546634.2024.2310631
More about...
Your opinion matters
4 votes - 25 days left ...
Related articles
Newsletter
Subscribe to get the best content related to Psoriasis and Psoriatic Arthritis delivered to your inbox